Erythromycin Ethylsuccinate Analysis Service

Erythromycin Ethylsuccinate Analysis Service

Our Erythromycin Ethylsuccinate (EES) Analysis Service Is a Powerful Tool for Quality Control

CD BioGlyco offers a comprehensive range of EES analysis services for different preparations. Our services encompass identification, dissolution testing, content determination, related compounds detection, and antibiotics microbial assays. With our expertise, we ensure accurate and reliable analysis for EES, meeting the diverse needs of our clients in the Pharmaceutical Field.

EES is the ethylsuccinate salt derivative of erythromycin, a versatile topical macrolide antibiotic exhibiting antibacterial properties. It permeates the bacterial cell membrane, forming reversible bonds with the 50S subunit of the bacterial ribosome. This interaction impedes bacterial protein synthesis, and the bacteriostatic or bactericidal nature depends on drug concentration at the infection site and the susceptibility of the specific organism.

Fig.1 The structure of EES. (CD BioGlyco)Fig.1 The structure of EES. (CD BioGlyco)

CD BioGlyco's comprehensive EES analysis service caters to various pharmaceutical preparations, ensuring accurate and reliable results across diverse formulations. Our methods are available for the following EES preparations.

  • EES tablets
  • EES dispersible tablets
  • EES capsules
  • EES Injection
  • Sterile EES
  • EES oral suspension
  • EES for oral suspension
  • EES and sulfisoxazole acetyl for oral suspension

Our adaptable methods and expertise in EES analysis extend to these diverse preparations, providing pharmaceutical companies with valuable insights into the quality, safety, and compliance of their EES products. Our EES analysis service encompasses a comprehensive range of tests to ensure the quality, safety, and compliance of clients' pharmaceutical products. Here's an overview of the testing we provide.

Fig.2 The standard content of EES analysis services. (CD BioGlyco)Fig.2 The standard content of EES analysis services. (CD BioGlyco)

Publication Data

Technology: Dose-based subgroup analysis, Pooled analysis

Journal: European Journal of Pediatrics

IF: 3.6

Published: 2021

Results: The trials included a broad range of erythromycin doses (3-50 mg/kg/day), categorized into "low" (≤12 mg/kg/day) and "high" (>12 mg/kg/day) based on motilin receptor stimulation. At low doses, neural motilin receptors were primarily activated, enhancing antral and intestinal contractile activity. High doses selectively stimulated muscle motilin receptors, inducing antral contractions. Motilin receptors are suggested throughout the GIT, challenging a clear dose-response relationship. Rescue therapy effectiveness was observed only with high-dose treatment, and both erythromycin ethyl-succinate and estolate salts demonstrated similar efficacy and safety, with earlier studies noting higher hepatotoxicity and cholestasis incidences with estolate.


  • Formulation development: Our analysis service aids in the formulation development of EES-based pharmaceuticals, ensuring the optimal composition and performance of the drug.
  • Quality control: Our EES analysis service plays a crucial role in quality control processes, verifying the identity, content, and purity of EES in pharmaceutical products.
  • Release testing: Our service is instrumental in release testing, evaluating the dissolution characteristics and release profile of EES formulations to meet related requirements.


  • CD BioGlyco's thorough analysis includes the detection and quantification of related compounds, contributing to safety assessments and compliance with safety standards.
  • By offering comprehensive analysis services, CD BioGlyco assists pharmaceutical companies in meeting specific standards for EES-based products.

At CD BioGlyco, we offer cutting-edge services to meet your Pharmaceutical and Biological Analysis needs. Our EES analysis service, tailored to ensure the quality and compliance of your formulations, includes comprehensive testing for sterility, dissolution, content, and more. Please do not hesitate to contact us for more details and we are looking forward to working for you.


  1. Basu, S.; Smith, S. Macrolides for the prevention and treatment of feeding intolerance in preterm low birth weight infants: a systematic review and meta-analysis. European Journal of Pediatrics. 2021, 180: 353-378.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.